@Article{Kralisz2021,
journal="Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej",
issn="1734-9338",
volume="17",
number="1",
year="2021",
title="Transcatheter transseptal mitral valve implantation with Edwards SAPIEN 3: the first experience of a single center",
abstract="In recent years, there has been a clear trend towards increased mitral bioprosthetic valve surgery in comparison to mechanical prostheses [1]. According to the ESC Guidelines mitral bioprostheses are recommended for patients > 70 years old or those with a life expectancy lower than the presumed durability of the bioprosthesis (class IIa/C). Importantly, the guidelines also recognize the prominence of quality of life after cardiosurgery and focus on patients’ preferences (class Ic), especially if long-term anticoagulation is nonoptimal (class Ic) [2]. Structural deterioration of mitral bioprostheses (structural valve deterioration – SVD) is the main limitation for their use. The average lifespan of a bioprosthetic valve is estimated at 16 years and the reoperation due to SVD affects as many as 75% of patients after a 20-year follow-up [3, 4]. Reoperation is usually associated with high risk of complications and mortality [5, 6].",
author="Kralisz, Paweł
and Frank, Marek
and Sobkowicz, Bożena
and Dobrzycki, Slawomir
and Hirnle, Tomasz",
pages="105--108",
doi="10.5114/aic.2021.104776",
url="http://dx.doi.org/10.5114/aic.2021.104776"
}